Bio-Rad Laboratories, Inc. (BIO) stock
Close on Nov 11, 2026Market cap $10.34BP/E 10.2Yield –
Bio-Rad Laboratories, Inc. grew revenue 1.4% to $2.59B over the twelve months to Sep 30, 2026. Operating income fell 127.6% to -$61.90M, moving the operating margin from 8.8% to -2.4%. Free cash flow was $329.10M, down 2.3% from a year earlier. At the latest close the market valued the company at $10.34B, 10.2 times its earnings.
Key statistics
Valuation at the latest close; fundamentals over the trailing twelve months, balances at Sep 30, 2026
Valuation
- Market cap
- $10.34B
- P/E ratio
- 10.2
- Price to sales
- 3.99
- Price to book
- 1.36
- Dividend yield
- –
- Free cash flow yield
- 3.18%
Fundamentals
- Revenue
- $2.59B
- Net income
- $1.02B
- EPS, diluted
- $37.97
- Free cash flow
- $329.10M
- Book value per share
- $282.17
- Diluted shares
- 27M
Trading
- Next earnings
- Feb 11, 2027 (estimated, during market hours)
- Previous close
- $386.48
- Open
- $388.31
- Day's range
- $382.76 – $389.99
- Volume
- 212,187
- Average volume (20 days)
- 257,180
- Index membership
- S&P MidCap 400 (since Nov 2024), Russell 1000, Russell 3000
- Beta (5 years)
- 1.03
- 52-week range
- $236.73 – $396.23
- RSI (14 days)
- 57.8
- Volatility (1 year)
- 36.3%
- Relative volume
- 0.79×
- WACC
- 9.6%
Index membership is inferred from the holdings of funds that track each index (IJH, SPMD, IWB, IWV), as reported to the SEC for Jun 30, 2026. Join dates come from quarterly fund reports since 2019, so they are accurate to the quarter.
Market cap history
Month-end market cap since 2009, using shares outstanding reported at the time
Total return vs. the S&P 500
Price change plus reinvested dividends, to the close on Nov 11, 2026. The S&P 500 is measured by the SPY fund.
| Period | BIO | S&P 500 | Difference | BIO per year | S&P 500 per year |
|---|---|---|---|---|---|
| 1 month | +5.4% | -2.4% | +7.8 pts | ||
| 3 months | +8.4% | -1.2% | +9.5 pts | ||
| Year to date | +27.4% | +12.3% | +15.1 pts | ||
| 1 year | +23.2% | +12.4% | +10.7 pts | ||
| 3 years | +27.0% | +78.8% | −51.9 pts | +8.3% | +21.4% |
| 5 years | -48.7% | +75.2% | −123.8 pts | -12.5% | +11.9% |
| 10 years | +131.6% | +311.1% | −179.6 pts | +8.8% | +15.2% |
Fifteen years at a glance
Fiscal years 2011 to 2025 and trailing twelve months, USD
Revenue
Gross profit
Operating income
Net income
EPS, diluted
Free cash flow
Press releases
Releases Bio-Rad Laboratories filed with the SEC as exhibits to Form 8-K or 6-K
- Results
- Results
- Results
- Results
- Results
- Results
About Bio-Rad Laboratories
Laboratory Analytical Instruments
Bio-Rad Laboratories, Inc. is a multinational manufacturer and distributor of life science research tools and clinical diagnostics solutions. The company operates through two core segments: Life Science and Clinical Diagnostics. The Life Science division provides instruments, reagents, consumables, and systems to separate, purify, characterize, and quantify biological materials such as cells, proteins, and nucleic acids. Its customers include universities, industrial research facilities, government bodies, pharmaceutical companies, and food testing laboratories. The Clinical Diagnostics segment supplies in vitro diagnostic systems, test kits, informatics software, and quality controls to hospital laboratories, reference laboratories, transfusion centers, and clinics.
Company profile, executives and historyBio-Rad Laboratories stock: common questions
What is Bio-Rad Laboratories's stock price?
BIO closed at $386.00 on Nov 11, 2026, down 0.12% on the day. Over the past 52 weeks it traded between $236.73 and $396.23.
What is Bio-Rad Laboratories's market cap?
Bio-Rad Laboratories was worth $10.34B at the close on Nov 11, 2026: the share price times the diluted shares outstanding.
What is BIO's P/E ratio?
BIO trades at 10.2 times earnings, based on diluted earnings per share of $37.97 over the twelve months to Sep 30, 2026.
How much revenue does Bio-Rad Laboratories make?
Bio-Rad Laboratories reported revenue of $2.59B for the twelve months to Sep 30, 2026, up 1.4% from a year earlier.
Does Bio-Rad Laboratories pay a dividend?
No. Bio-Rad Laboratories has not paid a cash dividend over the last twelve months.
When does Bio-Rad Laboratories report earnings next?
Bio-Rad Laboratories is expected to report Q4 FY2026 results on Feb 11, 2027, during market hours. The date is estimated from its past reporting pattern until the company confirms it.
How has BIO stock performed over the past year?
Including dividends, BIO returned +23.2% over the past year, against +12.4% for the S&P 500.
Who are Bio-Rad Laboratories's competitors?
Companies most similar to Bio-Rad Laboratories by business, industry and size include RVTY, BRKR, WAT, A, MTD.
See a number that looks wrong?